ClinicalTrials.Veeva

Menu

Dutch Sub Study: Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA). PET Sub Study

AstraZeneca logo

AstraZeneca

Status and phase

Completed
Phase 3

Conditions

Heart Failure
Rosuvastatin
Positron Emission Tomography (PET)

Treatments

Procedure: Positron emission tomography
Drug: Rosuvastatin

Study type

Interventional

Funder types

Industry

Identifiers

NCT00228514
4522IL/0098 Dutch SubStudy
D3562C00098

Details and patient eligibility

About

At one site, patients participating in the Corona main study are asked to participate in the PET-substudy. Before and 6 months after study medication is started a Positron Emission Tomography (PET-scan) is performed to study the effect of rosuvastatin in Chronic Heart Failure on myocardial perfusion (reserve)

Sex

All

Ages

60+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients fulfilling the in and exclusion criteria of the CORONA study and separate informed consent for participation in the sub study.

Exclusion criteria

  • See above

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems